Swedish Medtech Startup Medvasks raises € 917k to improve the anesthetic procedure while treating varicose veins

London MedavasA Swedish Medtech Company, today has announced the successful closure of a 917k finishing round to support the final product development stage for the final product development stage for their catheter devices and to prepare for the FDA regulatory approval in the United States.

The Financing Round attracted both existing owners and new investors.

We are very satisfied with the confidence of our investors to continueCatherine JohansonCEO of Medavas Abu. “This investment gives us the opportunity to take deciduous steps towards reaching the US market, which is an important milestone in our growth journey.

The Medvascus AB was founded by Michael å Conson in 2013 and in the past years it created a final prototype, granted patents and trademarks in all priority markets and performed first-man clinical studies.

Å Casan is a senior consultant in Interventional Radiology and has more than twenty years of experience with catheter -based treatment and diagnosis. Prior to that he was the head of the Endovascular Surgery Department at Vaskula Department, University Hospital. He now worked as a Senior Consultant at the Scandinavian Venus Center, Malm

He is the main owner of the Medavask AB and the inventor behind Solutio.

Medavask has developed and patent the medical device to improve the anesthetic method when treating the veins. Only for investigative use. Soluteo catheter is not evaluated by FDA and is not yet available for sale in the US.

Soluteo is designed to enable safe and specific local anesthesia during minimal offensive vascular methods, such as varicose veins (compatible with the thermal alleviation treatment fibers), a new level of control for physicians for the treatment of chronic venus disease and ease of the patient.

The initial focus of investment is to finance the production and examination of the final design of Soliuteo required for FDA exemption. The regulator is planned to submit for the first half of 2026.

Also, the FDA will increase an additional round during the Medevask 2025 for investment in clinical and advental activities required for the exemption certificate.

Medavask is also participating in the Incubator program of laughter – also located in London. Laughter is a leading initiative center that is special to advance life science and food science startups from concept to commercialization. To date, their flagship incubator program has supported more than 5 startups, acquiring more than $ 1.05 billion initiatives to facilitate their collective acquisition and contributed to 21 successful IPOs.



[publish_date

Leave a Reply

Your email address will not be published. Required fields are marked *